lactitol (Rx)

Brand and Other Names:Pizensy
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

unit-dose packet, oral powder

  • 10g/packet

multidose bottle, oral powder

  • 280g/bottle
  • 560g/bottle

Chronic Idiopathic Constipation

Indicated for chronic idiopathic constipation (CIC)

20 g PO qDay

Reduce to 10 g PO qDay for persistent loose stools

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and lactitol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Upper respiratory tract infection (9%)

            Flatulence (8%)

            Urinary tract infection (5%)

            Diarrhea (4%)

            Increased blood creatinine phosphokinase (4%)

            Abdominal distension (3%)

            Abdominal pain (3%)

            Increased blood pressure (3%)

            Severe diarrhea (1%)

            Elevated creatinine kinase (1%)

            Postmarketing Reports

            Hypersensitivity reactions (eg, rash, pruritus)

            Previous
            Next:

            Warnings

            Contraindications

            Known or suspected mechanical gastrointestinal obstruction

            Galactosemia

            Cautions

            Drug interaction overview

            • May reduce absorption of coadministered oral medications; administer oral medications at least 2 hr before or after lactitol
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Unknown whether maternal use will result in fetal exposure to drug

            Insufficient data available from case reports on use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

            Lactation

            No data available on the presence of lactitol in human or animal milk, effects on breastfed infants, or effects on milk production

            Unknown whether minimal systemic absorption of lactitol by adults will result in a clinically relevant exposure to breastfed infants

            Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for lactitol and any potential adverse effects on the breastfed infant from lactitol or from the underlying maternal condition

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Osmotic laxative; exerts an osmotic effect ,causing an influx of water into the small intestine and resulting in a laxative effect in the colon

            Absorption

            Minimally absorbed systemically after oral administration

            Peak plasma concentration: 776 ng/mL

            Peak plasma time: 3.6 hr

            AUC: 6,019 ng⋅hr/mL

            Effect of food

            • Peak plasma concentration and AUC values increase greater than 2-fold under fasted conditions compared with fed conditions

            Elimination

            Half-life: 2.4 hr

            Minimally absorbed in the small intestine

            Unabsorbed lactitol is expected to be degraded into organic acids in the colon and is minimally excreted in the feces

            Previous
            Next:

            Administration

            Oral Preparation

            Multidose bottle

            • Bottle top measures 10 grams of powder
            • 10-gram dose: Fill measuring cap once
            • 20-gram dose: Fill measuring cap twice
            • Pour measured powder into an empty glass
            • Add 4-8 ounces of water, juice, or other common beverages (eg, coffee, tea, soda) to glass containing the powder; stir thoroughly to dissolve
            • Drink entire contents of glass

            Unit-dose packets

            • Pour contents of 1-2 unit-dose packets, as prescribed, into an empty 8-ounce glass.
            • Add 4-8 ounces of water, juice, or other common beverages (eg, coffee, tea, soda) to the glass containing the powder; stir thoroughly to dissolve
            • Drink entire contents of the glass

            Oral Administration

            Preferably taken with meals

            Administer oral medications at least 2 hr before or after dose

            Storage

            Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59- 86ºF)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.